Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, DUR928, norUDCA, HTD1801, IDN-7314, STP705) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Oppor

Primary Sclerosing Cholangitis Market, by Drug (BT1023, GS-9674, NGM282, OCA, LUM001, DUR928, norUDCA, HTD1801, IDN-7314, STP705) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Primary sclerosing cholangitis (PSC) is generally a progressive disease that eventually culminates in cirrhosis with complications (portal hypertension, end-stage liver disease, and hepatic failure). Bile ducts carry the digestive liquid bile from liver to small intestine. In primary sclerosing cholangitis, inflammation causes scars within the bile ducts. These scars make the ducts hard and narrow and gradually cause serious liver damage. A majority of people with primary sclerosing cholangitis also have inflammatory bowel disease, such as ulcerative colitis or Crohn's disease. Primary sclerosings cholangitis is often diagnosed before symptoms appear when a routine blood test or an X-ray taken for an unrelated condition shows liver abnormalities. Early signs and symptoms often include fatigue, itching, yellow eyes and skin (jaundice), and abdominal pain. This disease predominantly affects men between the age of 25 and 40 years. The damage to the ducts causes accumulation of bile acids, essential components of bile to build up in the liver leading to liver tissue damage, portal hypertension (high blood pressure in the vessels connecting the liver and the gut), and liver failure, and may increase the risk of liver cancer.

Market Dynamics

Increasing research and development activities on the drugs used for the treatment of primary sclerosing cholangitis is expected to drive the market growth over the forecast period. For instance, in June 27 2022, Chemomab Therapeutics Ltd., a clinical-stage biotech company focused on the discovery and development of innovative therapeutics for fibrotic and inflammatory diseases with high unmet need, reported on two presentations at important scientific meetings. The presentations included preclinical data that support the role of the soluble protein CCL24 in the pathophysiology of liver diseases such as primary sclerosing cholangitis (PSC), and also indicate that Chemomab's CCL24 neutralizing antibody CM-101 demonstrates translatable patterns of extracellular matrix (ECM) remodeling in preclinical and clinical studies.

Key features of the study:

• This report provides an in-depth analysis of the global primary sclerosing cholangitis market, market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global primary sclerosing cholangitis market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global primary sclerosing cholangitis market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global primary sclerosing cholangitis market

Detailed Segmentation:

• Global Primary Sclerosing Cholangitis Market, By Drug:
• BTT1023
• GS-9674
• NGM282
• OCA
• Cenicriviroc
• LUM001
• DUR928
• norUDCA
• HTD1801
• IDN-7314
• STP705
• Global Primary Sclerosing Cholangitis Market, By Region:
• North America

By Country

• U.S.
• Canada
• Latin America

By Country

• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe

By Country

• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific

By Country

• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East

By Country

• GCC
• Israel
• Rest of Middle East
• Africa

By Region/Country

• South Africa
• Central Africa
• North Africa
• Company Profiles
• Acorda Therapeutics, Inc.*

Company Highlights

Products Portfolio

Key Highlights

Financial Performance

Strategies

• Gilead Sciences, Inc.
• NGM Biopharmaceuticals, Inc.
• Intercept Pharmaceuticals, Inc.
• Falk Pharma GmbH
• Allergan Plc.
• Shire Plc.
• Durect Corporation
• Conatus Pharmaceuticals, Inc.
• Sirnaomics, Inc.
• Shenzhen HighTide Biopharmaceuticals Ltd.

“*” marked represents similar segmentation in other categories in the respective section.